Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent) and Alemtuzumab (Campath).

Trial Profile

Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent) and Alemtuzumab (Campath).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Pentostatin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 11 Jan 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 11 Jan 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top